The company has $400 million, enough cash to potentially build off results from an early-stage leukemia yet this quarter.

NEW YORK CITY, NY / ACCESS Newswire / November 3, 2025 / In 2022, Zealthy Founder and CEO Kyle Robertson launchedZealthywith a clear mission: make high-quality healthcare more accessible and ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech ...

Metsera's shareholders are scheduled to meet on November 13 to decide on Novo Nordisk's offer of around $8.5 billion, while ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

"Every day, I got on the scales and I still weighed exactly the same as before," Leith, 85, told U.K. paper 'The Times' ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...

Berkshire reported $13.485 billion in operating profit from its wholly owned businesses in the third quarter, a 34% increase ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...